Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1975 Sep;56(3):719-24.
doi: 10.1172/JCI108143.

Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon

Clinical Trial

Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon

J J Lertora et al. J Clin Invest. 1975 Sep.

Abstract

The purpose of this study was to test the hypothesis that oral administration of a low dose of practolol in man produces selective beta-1 receptor blockade, whereas oral administration of a high dose blocks both beta-1 and beta-2 receptors. Normal men were studied 2-4 h after a single oral dose of practolol (1.5 or 12 mg/kg) and after placebo. Effects on beta-1 receptors were studied by measuring heart rate responses to exercise. Effects on beta-2 receptors were tested by measuring forearm vascular responses to brachial arterial infusions of isoproterenol. Neither dose of practolol altered base-line heart rate, forearm vascular resistance, and arterial pressure, Both low and high doses significantly attenuated heart rate responses to exercise. Forearm vasodilator responses to isoproterenol were attenuated by the high dose, but not the low dose, of practolol. Serum concentrations of practolol 2 h after administration of the drug and at the time of the studies of forearm vascular responses averaged 0.5+/-0.1 (SE) and 5.9+/-1.0 mug/ml for low and high doses of practolol, respectively. The results indicate that the phenomenon of selective beta-1 receptor blockade in man is related to the dose and serum concentration of practolol selectively block beta-1 receptors; a high dose and serum concentrations block both beta-1 and beta-2 receptors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Invest. 1964 Feb;43:316-22 - PubMed
    1. Lancet. 1964 May 16;1(7342):1080-1 - PubMed
    1. J Physiol. 1953 Jul;121(1):1-27 - PubMed
    1. Clin Pharmacol Ther. 1974 Nov;16(5 Part 1):750-60 - PubMed
    1. Clin Pharmacol Ther. 1973 Mar-Apr;14(2):175-81 - PubMed

Publication types